Request Call Back

Contact Us

Case Review Form
*    Denotes required field.

Describe accident or indicate name of drug or device

   * First Name 

   * Last Name 

   * Email 


   * Please describe your case:

What injury have you suffered?

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Samsca (tolvaptan) Liver Injury Side Effects Lawsuits

Samsca Linked to Fatal Liver Damage

Tolvaptan Linked to Liver Enzymes Increase and Hepatic Injury Risks

Samsca Linked to Fatal Liver Damage, New Restriction on Length of Use

Samsca is a medication manufactured by Otsuka America Pharmaceutical and is approved for hyponatremia, a metabolic condition in which there is not enough sodium (salt) in the body fluids outside the cells. According to a recent Drug Safety Communication,  the U.S. Food and Drug Administration (FDA) has determined that "the drug Samsca (tolvaptan) should not be used for longer than 30 days and should not be used in patients with underlying liver disease because it can cause liver injury, potentially leading to liver transplant or death. [The] FDA has worked with the manufacturer to revise the Samsca drug label to include new limitations."

A prior Drug Safety Communication was issued by the FDA in January 2013, stating that Samsca has been linked to potentially irreversible and fatal liver injury.  The communication also states that doctors should perform liver tests on Samsca patients who report symptoms indicating liver injury.

A clinical trial of Tolvaptan on patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) has shown that use of Samsca may lead to abnormally high levels of liver enzymes; these findings prompted the company to issue a letter to healthcare providers warning that Samsca may cause irreversible and potentially fatal liver injury. If you or a loved one developed a liver injury after taking Samsca, our attorneys would like to speak with you. Call Parker Waichman LLP today for a free, no-obligation evaluation of your case.    

Clinical Trials Show Samsca® May Cause Potentially Fatal Liver Injury in ADPKD Patients

On January 22, 2013 Otsuka America Pharmaceutical issued a letter to healthcare providers warning of significant liver injury associated with the use of Samsca. This warning was based on a 3-year clinical trial of some 1,400 patients with ADPKD; three of these patients developed levels of serum alanine aminotransferase (ALT) that were three times as high as the upper limit of normal as well as serum total bilirubin levels more than twice the upper limit of normal. Alanine aminotransferase (ALT) is an enzyme found in the liver and bilirubin is waste product of the normal breakdown of red blood cells; the levels of these substances are measured in order to assess liver damage and injury. According to the letter, the three cases are “probably or highly likely to be caused by tolvaptan,” suggesting that “Samsca (tolvaptan) has the potential to cause irreversible and potentially fatal liver injury.”

The letter also said that patients taking Samsca had significantly higher levels of ALT compared to those taking a placebo. In 4.4 percent (42 out of 958) of ADPKD patients taking Samsca, ALT levels were three times higher than the upper limit of normal compared to the 1 percent (5 out of 958) of patients on placebo. After discontinuing Samsca, the affected patients gradually improved, the letter said.

Samsca is not approved for ADPKD; it is approved for the treatment of clinically significant hypervolemic or euvolomic hyponatremia, or low levels of sodium in the blood. Although previous findings have not indicated liver damage with the use of Samsca in the past, Otsuka states that this data is inadequate to rule out the possibility that Samsca increases the risk of irreversible and potentially fatal liver injury. Furthermore, the company’s letter said that the ability to recover from such injury may be inhibited in patients with hyponatremia “in the setting of underlying liver disease, including cirrhosis”.

Liver Injury Symptoms

Otsuka’s letter states that healthcare professionals should perform tests to assess liver function in Samsca patients who report symptoms of liver injury, including:

  • Fatigue
  • Anorexia
  • Right upper abdominal discomfort
  • Dark urine
  • Jaundice (yellowing of the skin and/or eyes)

If liver injury is suspected, Otsuka said, “Samsca should be promptly discontinued, appropriate treatment should be instituted, and investigations should be performed to determine probable cause.”

Legal Help for Victims of Samsca Side Effects

If you or a loved one suffered from a liver injury after taking Samsca, you may have valuable legal rights. Please fill out our online form or call 1(800)-YOURLAWYER (1-800-968-7529) to speak with one of our experienced drug injury lawyers today.


Samsca (tolvaptan) Liver Injury Side Effects LawsuitsRSS Feed

Risk of Liver Injury Seen with Samsca

May 31, 2013
Clinical trials have revealed drug-induced liver injury in patients taking Samsca (tolvaptan). Samsca was being tested for an unapproved use in patients diagnosed with autosomal dominant polycystic kidney disease (ADPKD) at higher doses than the approved indication and in long-term use. The Medicines and Healthcare products Regulatory Agency (MHRA) recommends liver function testing in patients taking Samsca who report responses that suggest liver injury. Also, treatment should be stopped when...

FDA Warns Samsca Use May Lead to Serious Liver Damage

May 2, 2013
Data from some large clinical trials prompted the U.S. Food and Drug Administration (FDA) to announce that Samsca may cause liver damage. The study found that Samsca (tolvaptan) should be used no longer than 30 days in patients with no underlying liver disease and should never be used by patients diagnosed with underlying liver disease, said Renal & Urology News. A selective vasopression V2-receptor antagonist, Samsca is indicated for the treatment of patients who are diagnosed with...

More Samsca (tolvaptan) Liver Injury Side Effects Lawsuits News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo